- Pharmaceutical Products
- Products By Brand Name
- Products By Dosage Form
- Products By Generic Name
- Products By Therapeutic Class
Find a product
Find Generic
Lantidex
Dexlansoprazole
Description:
Lantidex® (Dexlansoprazole) capsule is a Proton Pump Inhibitor (PPI), which inhibit gastric acid secretion. Dexlansoprazole is the R-enantiomer of lansoprazole. Dexlansoprazole is supplied as a Dual Delayed Release (DDR) formulation in a capsule for oral administration. Dexlansoprazole capsule contains a mixture of two types of enteric coated granules with different pH-dependent dissolution profiles.
Lantidex® (Dexlansoprazole) capsule is a Proton Pump Inhibitor (PPI), which inhibit gastric acid secretion. Dexlansoprazole is the R-enantiomer of lansoprazole. Dexlansoprazole is supplied as a Dual Delayed Release (DDR) formulation in a capsule for oral administration. Dexlansoprazole capsule contains a mixture of two types of enteric coated granules with different pH-dependent dissolution profiles.
Indications:
Healing of Erosive Esophagitis: Dexlansoprazole is indicated for healing of all grades of Erosive Esophagitis (EE) for up to 8 weeks.
Maintenance of Healed Erosive Esophagitis: Dexlansoprazole is indicated to maintain healing of EE and relief of heartburn for up to 6 months.
Symptomatic Non-Erosive Gastroesophageal Reflux Disease: Dexlansoprazole is indicated for the treatment of heartburn associated with symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD) for 4 weeks.
Healing of Erosive Esophagitis: Dexlansoprazole is indicated for healing of all grades of Erosive Esophagitis (EE) for up to 8 weeks.
Maintenance of Healed Erosive Esophagitis: Dexlansoprazole is indicated to maintain healing of EE and relief of heartburn for up to 6 months.
Symptomatic Non-Erosive Gastroesophageal Reflux Disease: Dexlansoprazole is indicated for the treatment of heartburn associated with symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD) for 4 weeks.
Mode of Action:
Dexlansoprazole is a PPI that suppresses gastric acid secretion by specific inhibition of the (H+,K+)-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Dexlansoprazole blocks the final step of acid production.
Dexlansoprazole is a PPI that suppresses gastric acid secretion by specific inhibition of the (H+,K+)-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Dexlansoprazole blocks the final step of acid production.
Other Brands From Same Therapeutic Class
